Actively Recruiting
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Led by Huons Co., Ltd. · Updated on 2026-01-13
206
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
CONDITIONS
Official Title
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 19 years and older
- Participants diagnosed with primary open angle glaucoma or ocular hypertension
- Have fully understood the study and voluntarily given written informed consent
You will not qualify if you...
- Acute or chronic angle-closure glaucoma
- Congenital glaucoma or secondary open-angle glaucoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kangbuk Samsung Hospital
Seoul, South Korea
Actively Recruiting
Research Team
R
Rang Lee
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here